SBC files 8‑K with Q3 2025 results press release and presentation

Rhea-AI Filing Summary

SBC Medical Group Holdings Incorporated filed an 8‑K stating it issued a press release announcing results for the quarter ended September 30, 2025, and posted an investor presentation.

These materials are attached as Exhibits 99.1 and 99.2 and are furnished under Item 2.02, not filed. The company’s securities trade on Nasdaq: common stock SBC and redeemable warrants SBCWW. The report was signed by Chief Financial Officer Yuya Yoshida on November 14, 2025.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001930313false0001930313sbc:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember2025-11-142025-11-140001930313sbc:CommonStock0.0001ParValuePerShareMember2025-11-142025-11-1400019303132025-11-142025-11-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

SBC Medical Group Holdings Incorporated

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41462	88-1192288
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
200 Spectrum Center Dr. STE 300
Irvine, California				92618
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 949 593-0250

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		SBC		The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share		SBCWW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 14, 2025, SBC Medical Group Holdings Incorporated (the “Company”), issued a press release announcing its results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Additionally, on November 13, 2025, the Company posted an investor presentation to its website (https://sbc-holdings.com/en/ir/ir-presentation ), regarding results for the quarter ended September 30, 2025 which presentation is attached hereto as Exhibit 99.2 and incorporated by reference herein.

The information furnished under Item 2.02, including Exhibit 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated November 14, 2025, entitled “SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results”
99.2		Investor Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SBC Medical Group Holdings Incorporated
Date:	November 14, 2025	By:	/s/ Yuya Yoshida
			Yuya Yoshida Chief Financial Officer

FAQ

What did SBC (SBC) announce in this 8‑K?

It disclosed that a press release with results for the quarter ended September 30, 2025, and an investor presentation were issued and attached as Exhibits 99.1 and 99.2.

Which reporting period does the update cover for SBC?

The update covers the quarter ended September 30, 2025.

Where can investors find SBC’s investor presentation?

The presentation was posted on the company’s website and attached as Exhibit 99.2.

How are the exhibits treated for liability purposes?

They are furnished under Item 2.02 and not deemed filed under Section 18 of the Exchange Act.

What exhibits are included with this SBC 8‑K?

Exhibit 99.1 is the press release dated November 14, 2025; Exhibit 99.2 is the investor presentation; Exhibit 104 is the cover page Inline XBRL data file.

What are SBC’s Nasdaq tickers?

Common stock trades as SBC; redeemable warrants trade as SBCWW.

Who signed SBC’s 8‑K and when?

Chief Financial Officer Yuya Yoshida signed on November 14, 2025.